The New York Times Commends Memorial Sloan-Kettering’s Stance on a Costly Cancer Drug

1 comment By Julie Grisham, MS, Science Writer/Editor   |  Friday, November 16, 2012 Memorial Sloan-Kettering has been praised for taking a stand on the price for a new cancer drug that costs more than twice as much as another, similar drug. read more

Link:
The New York Times Commends Memorial Sloan-Kettering’s Stance on a Costly Cancer Drug

Share and Enjoy:
  • Print
  • Digg
  • StumbleUpon
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks
  • Add to favorites
  • email
  • LinkedIn
  • RSS
  • Tumblr
Share